Werbung
Werbung
VVOS
Vivos Therapeutics, Inc. Common Stock
2.05
USDGesponsert
-0.17
-7.66%
09. Jan., 15:59 UTC -5
Geschlossen
Nach-Markt
2.07
+0.02
+0.93%
VVOS Ergebnisberichte
Positives Überraschungsverhältnis
VVOS übertreffen die 8 der letzten 19Schätzungen.
42%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.71M
/-$0.45
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-15.82%
/-8.16%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+54.40%
/+60.71%
Vivos Therapeutics, Inc. Common Stock earnings per share and revenue
On 19. Nov. 2025, VVOS reported earnings of -0.49 USD per share (EPS) for Q3 25, beating the estimate of -0.52 USD, resulting in a 5.81% surprise. Revenue reached 6.78 million, compared to an expected 4.91 million, with a 38.20% difference. The market reacted with a -10.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.45 USD, with revenue projected to reach 5.71 million USD, implying an decrease of -8.16% EPS, and decrease of -15.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-Überraschung
-
FAQ
What were Vivos Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.49, beating estimates by 5.81%, and revenue of $6.78M, 38.2% above expectations.
How did the market react to Vivos Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -10.17%, changed from $2.36 before the earnings release to $2.12 the day after.
When is Vivos Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for Vivos Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.45 and revenue of $5.71M for Q4 2025.
Which companies are reporting earnings today?
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung